Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values (Q46876288)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 June 2014

Language	Label	Description	Also known as
English	Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values	scientific article published on 21 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

Michael A. Pfaller

6

object named as

Michael A Pfaller

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

Mariana Castanheira

1

object named as

Mariana Castanheira

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

2

object named as

Shawn A Messer

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

5

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

author name string

Paul R Rhomberg

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

Rachel R Dietrich

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

publication date

21 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

178

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

1-2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

1-9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

https://scigraph.springernature.com/pub.10.1007/s11046-014-9772-2

0 references

Impact of first-line antifungal agents on the outcomes and costs of candidemia

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Fungal sepsis: optimizing antifungal therapy in the critical care setting

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Antifungal use in hospitalized adults in U.S. academic health centers

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational s

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Emerging opportunistic yeast infections

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Emerging moulds: epidemiological trends and antifungal resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Breakthrough invasive candidiasis in patients on micafungin

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillan

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Azole-resistance in Aspergillus: proposed nomenclature and breakpoints

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Clinical significance of azole antifungal drug cross-resistance in Candida glabrata

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Update on Antifungal Resistance and its Clinical Impact

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9772-2

21 January 2018

Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012

1 reference

https://pubmed.ncbi.nlm.nih.gov/24952015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr

1 reference

https://pubmed.ncbi.nlm.nih.gov/24952015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24952015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11046-014-9772-2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24952015

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46876288&oldid=2135564531"